Riboflavin
It is involved in a variety of metabolic processes, including energy production, cellular growth and development, and the maintenance of healthy skin and vision.
Riboflavin is found in a range of food sources, such as dairy products, eggs, meat, poultry, fish, and leafy green vegetables.
Deficiency in riboflavin can lead to a condition called ariboflavinosis, which can cause symptoms such as cracks and sores at the corners of the mouth, scaly skin, and impaired vision.
Adequate intake of riboflavin is important for maintaining overall well-being and preventing health issues.
Reserchers can utilize PubComapre.ai, an AI-driven platform, to optimize their riboflavin research by easily locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Most cited protocols related to «Riboflavin»
The OBS had combined the contributions of both diet and lifestyle. To investigate whether diet or lifestyle factors significantly contributed to the OBS-LTL association, respectively, we calculated a dietary OBS by excluding four lifestyle variables: cotinine, alcohol consumption, BMI, and physical activity from the OBS measures that have been described above and calculated a lifestyle OBS that only included these four variables [52 (link)].
We selected 24 nutrients for inclusion in the PANDiet: protein, total carbohydrate, fibre, total fat, saturated and polyunsaturated fatty acids, cholesterol, thiamin, riboflavin, niacin, folate, vitamins A, B-6, B-12, C, D and E, calcium, magnesium, zinc, phosphorus, potassium, iron and sodium. This selection was based on the available current national nutritional recommendations for French [25] –[30] and US adults [31] –[38] , and the availability of data in ENNS and NHANES food composition databases.
We used the probabilistic approach developed by the Institute of Medicine [20] to estimate, for each individual, if the usual intake of a nutrient was adequate. The calculation of the probability takes into account the number of days of dietary data, the mean intake and the day-to-day variability of intake, the nutrient reference value and the interindividual variability (
For each nutrient, adequate intake was assumed to be the level likely to satisfy the nutrient requirements and unlikely to be excessive and elicit adverse health effects. Therefore, we assessed separately the probability that the intake was adequate inasmuch as it satisfied the requirement, on one hand, and the probability that it was not excessive, on the other hand. Consequently, the PANDiet was constructed based on two sub-scores - the Adequacy sub-score and the Moderation sub-score.
The Adequacy sub-score was calculated as the average of the probability of adequacy for items for which the usual intake should be above a reference value, multiplied by 100. According to the nutrient reference values, the probability was determined as follows:
The Moderation sub-score was calculated as the average of the probability of adequacy for items for which the usual intake should not exceed a reference value and penalty values, multiplied by 100. According to the nutrient reference values, the probability was determined as follows:
For other vitamins and minerals with available upper tolerable limits but where the risk of excessive intake is low, we used a penalty value system: a value equal to 0 was generated when the average intake of a nutrient exceeded the upper tolerable limit of intake.
The PANDiet score is the average of the Adequacy and Moderation sub-scores. In principle, the score ranges from 0 to 100; the higher the score, the better the diet quality.
A French implementation of the PANDiet (
A HeLa (‘Kyoto' strain) cell line stably co-expressing H2B-mRFP and MyrPalm-mEGFP18 (link), was used for live-cell microscopy experiments. H2B-mRFP was imaged as a reference marker to quantify cell proliferation, mitotic duration and chromosome missegregation in the control cells (dimethylsulfoxide) that were not stained with SiR–Hoechst. HeLa cells were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin–streptomycin (Sigma), 0.5 μg ml−1 puromycin and 500 μg ml−1 G418. For live-cell imaging experiments, cells were grown either in LabTek II chambered coverslips (ThermoScientific) or 96-well plastic-bottom plates (μclear; Greiner Bio-One Ltd.), in DMEM containing 10% (v/v) FBS and 1% (v/v) penicillin–streptomycin, but without riboflavin and phenol red to reduce background fluorescence. For wide-field and confocal time-lapse imaging, SiR–Hoechst, SYTO 61 (Life Technologies) and Vybrant DyeCycle Ruby (Life Technologies) were added between 30 min and 2 h before imaging at the concentrations as indicated in the main text.
Most recents protocols related to «Riboflavin»
Example 2
100 mg of the Sarcodon aspratus extracts according to the present invention;
an appropriate amount of a vitamin mixture;
70 μg of vitamin A acetate;
1.0 mg of vitamin E;
0.13 mg of vitamin B1;
0.15 mg of vitamin B2;
0.5 mg of vitamin B6;
0.2 μg of vitamin B12;
10 mg of vitamin C;
10 μg of biotin;
1.7 mg of nicotinic acid amide;
50 μg of folate;
0.5 mg of calcium pantothenate;
an appropriate amount of a mineral mixture;
1.75 mg of ferrous sulfide;
0.82 mg of zinc oxide;
25.3 mg of magnesium carbonate;
15 mg of potassium phosphate monobasic;
55 mg of dicalcium phosphate;
90 mg of potassium citrate;
100 mg of calcium carbonate; and
24.8 mg of magnesium chloride.
The composition ratio of the vitamins and the mineral mixture described above may be determined according to a composition ratio used in general functional health foods, and the combination ratio of the vitamins and the mineral mixture may be arbitrarily determined. According to a conventional method of preparing functional health foods, these components are mixed, granules are prepared, and the granules are used to prepare a composition for a functional health food.
Example 6
This example provides a representative example of an aqueous solution to be used in a method described herein. The composition may contain the following ingredients:
The aqueous solution is formulated in physiological saline and adjusted to about pH 7.4, thereby minimizing any injecting pain beyond the needle prick. In addition, the aqueous solution may be optionally supplemented with a preservative (e.g., benzyl alcohol), a chemical stabilizer (e.g., gentisic acid), and/or an additional bioactive agent (e.g., platelet-rich plasma) depending on anticipated delivery method, shelf-life, and intended effects.
Example 7
The purpose of this example is to evaluate the efficacy of a composition described herein in treating the signs of aging present on facial skin. A composition is prepared as in Example 6.
Two groups of human subjects (8-10 subjects per group) are injected with the composition or physiological saline (control) twice a day for a period of 29 days. At the end of the 29 day test period, the subjects are polled regarding various aspects of the effectiveness of the composition described herein in treating and/or minimizing signs of aging present on the skin. The following aspects of the composition described herein are evaluated:
-
- (1) effectiveness of the composition described herein in improving the smoothness and/or softness of skin (i.e., making the skin feel smoother and softer following treatment);
- (2) effectiveness of the composition described herein in improving the overall appearance of skin;
- (3) effectiveness of the composition described herein in evening out skin tone and texture;
- (4) effectiveness of the composition described herein in improving the clarity and/or radiance of skin;
- (5) effectiveness of the composition described herein in making the skin look younger; and
- (6) effectiveness of the composition described herein in making wrinkles appear softer and/or less prominent.
- (7) effectiveness of the composition described herein in increasing the degree of hydration of the skin.
Patients treated with the composition exhibit improvement in one or more of the symptoms described herein.
Example 8
The purpose of this example is to evaluate the efficacy of a composition described herein in treating the signs of aging present on facial skin. A composition is prepared as in Example 6.
Two groups of human subjects (8-10 subjects per group) are injected with the composition or physiological saline (control) on days 1, 3, 7, 10, 14, 21, 30, 60, and 90 of treatment. At the end of the 90-day test period, the subjects are polled regarding various aspects of the effectiveness of the composition described herein in treating and/or minimizing signs of aging present on the skin. The following aspects of the composition described herein are evaluated:
-
- (1) effectiveness of the composition described herein in improving the smoothness and/or softness of skin (i.e., making the skin feel smoother and softer following treatment);
- (2) effectiveness of the composition described herein in improving the overall appearance of skin;
- (3) effectiveness of the composition described herein in evening out skin tone and texture;
- (4) effectiveness of the composition described herein in improving the clarity and/or radiance of skin;
- (5) effectiveness of the composition described herein in making the skin look younger; and
- (6) effectiveness of the composition described herein in making wrinkles appear softer and/or less prominent.
- (7) effectiveness of the composition described herein in increasing the degree of hydration of the skin.
Patients treated with the composition exhibit improvement in one or more of the symptoms described herein.
While preferred embodiments have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the embodiments. It should be understood that various alternatives to the embodiments described herein may be employed. It is intended that the following claims define the scope of the embodiments and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Example 5
An aqueous solution containing the following ingredients:
-
- about 1500 to about 6250 meg cobalamin (vitamin B12);
- about 150 to about 250 mg ascorbic acid (vitamin C);
- about 30 to about 50 mg nicotinamide (vitamin B3);
- about 4.5 to about 7.5 mg thiamine (vitamin B1);
- about 0.1 to about 0.3 mg pyridoxine HCl (vitamin B6);
- about 2.7 to about 4.5 mg riboflavin 5-phosphate sodium (vitamin B2);
- about 7.5 to about 15 mg pantothenic acid (vitamin B5);
- about 0.08 to about 0.125 mg Zinc sulfate heptahydrate; and
- about 1 ml q.s., sterile water for injection
The aqueous solution is formulated in physiological saline and adjusted an acceptable pH in the range of about 6.5 to about 7.5 to 7.4, thereby minimizing any injecting pain beyond the needle prick. The aqueous solution may be optionally supplemented with a preservative (e.g., from about 0.01% to about 2% benzyl alcohol), a chemical stabilizer (e.g., from about 0.01% to about 2% gentisic acid), and/or an additional bioactive agent (e.g., from about 0.01% to about 2% hyaluronic acid) depending on anticipated delivery method, shelf-life, and intended effects.
Example 3
Clostridium histolyticum ATCC 21000, strain 004 was inoculated into the starting culture with M #1 or M #2 and incubated at 37° C. for 16 hours. Ten milliliters of the starting culture (M #1 or M #2) and 10 mL Mg/vitamin solution (prepared separately by dissolving 8 g MgSO4, 1.2 g ferrous sulfate, 0.05 g riboflavin, 0.1 g Niacin, 0.1 g Calcium pantothenate, 0.1 g pimelic acid, 0.1 g pyridoxine, and 0.1 g thiamine in 1100 mL water, followed by sterilization by 0.22 μm filtration) was then transferred to each liter of M #3 or M #4 (or a variation thereof), and incubated for 22 hours. Clostridium histolyticum grew well with the OD600 reaching >2.5.
Example 3
Clostridium histolyticum ATCC 21000, strain 004 was inoculated into the starting culture with M #1 or M #2 and incubated at 37° C. for 16 hours. Ten milliliters of the starting culture (M #1 or M #2) and 10 mL Mg/vitamin solution (prepared separately by dissolving 8 g MgSO4, 1.2 g ferrous sulfate, 0.05 g riboflavin, 0.1 g Niacin, 0.1 g Calcium pantothenate, 0.1 g pimelic acid, 0.1 g pyridoxine, and 0.1 g thiamine in 1100 mL water, followed by sterilization by 0.22 pm filtration) was then transferred to each liter of M #3 or M #4 (or a variation thereof), and incubated for 22 hours. Clostridium histolyticum grew well with the OD600 reaching >2.5.